Survivin Gene Polymorphism Association with Tongue Squamous Cell Carcinoma

Leila Vazifeh Mostaan,1 Azin Tabari,2 Parvin Amiri,3 Mohammadtaghi Khorsandi Ashtiani,2 Aydin Mahdkhah,2 Nasrin Yazdani,2 Mahmood Khaniki,4 Azadeh Tabari,1 Javad Tavakkoly-Bazzaz,3 and Mahsa M. Amoli3

Subject: Survivin expression is correlated with tumor aggressiveness and severity in head and neck carcinoma. A polymorphism at position −31 (G/C) (rs 9904341) has been associated with cancer risk in several studies. We evaluated the correlation of this polymorphism with clinical manifestation of patients with tongue squamous cell carcinoma (SCC) in an Iranian population. 

Methods: Paraffin-embedded tissue sections from patients with tongue SCC (n = 91) were evaluated for association between the survivin −31 (G/C) polymorphism and tumor staging, pathological grade, lymph node metastasis, tumor size, and recurrence of tumor.

Results: There was a significant increase of presence of allele C in patients who were at stages III and IV compared to patients with lower stages [GC + CC vs. GG, p = 0.025, odds ratio [OR] 2.76, 95% confidence interval [CI] [1.03–7.4)]. In addition, presence of allele C was significantly decreased in patients with T1 tumor size compared to patients with larger tumor size (p = 0.03, OR 0.6, 95% CI [0.2–2.03]).

Conclusion: Presence of the C allele was significantly associated with tumor stage and size; therefore, survivin might be an important marker in the prognosis of tongue SCC that requires further investigation.

Introduction

Carcinoma of the oral cavity comprises ~14% of head and neck malignancies with tongue carcinoma as the most common type of oral carcinoma presenting as the squamous cell carcinoma (SCC) type in the majority of cases (86%) and causing high morbidity (Funk et al., 2002).

The prevalence of tongue SCC is increased in the world, and despite, aggressive therapeutic strategies have remained ubiquitous with high morbidity and mortality rate (Funk et al., 2002). The 5-year survival rates in the best cases are <60% (Funk et al., 2002).

In a study by Schantz et al. (2002), the prevalence of tongue carcinoma has been increased up to 60% in patients younger than 40 years of age, between 1973 and 1984, and has remained the same since then, while the prevalence of other types of oral cavity carcinoma did not change at the same period. Despite this increase, the 5-year determinant survival of these patients was better than that for older individuals (Schantz et al., 2002).

The exact etiology for the increased prevalence of disease is not clear, and some factors, including drug addiction, smoking, and HPV infection, were suggested (Woods et al., 1993). Overall, two main mechanisms have been proposed for the pathogenesis of head and neck carcinomas: environmental carcinogens and genetic susceptibility (Thomas et al., 2005; Ferrari et al., 2009).

Genetic mutations and abnormal expression of molecular markers have been reported in most cases (Thompson, 1995; Forastiere et al., 2001; Belbin et al., 2008; Ferrari et al., 2009). There are small, rather controversial, data regarding the molecular mechanisms involved in pathogenesis of tongue carcinoma (Thompson, 1995). Recent evaluations are mainly based on clinical examination and histopathology results. More information on molecular and genetic mechanisms involved will be valuable for the assessment of prognosis and disease outcome.

Apoptosis and unbalanced cell proliferation play a critical role in development of cancers (Melet et al., 2008). The human inhibitor of apoptosis protein (IAP) family consists of eight members of baculoviral repeat containing BIRC 1 to BIRC 8 (Johnson and Howerton, 2004; Knauser et al., 2007). High expression of survivin (BIRC 5) and XIAP (BIRC 4) is critical for apoptosis suppression in human solid tumors (Krepeka et al., 2009). Survivin has unique propriety because of its bifunctional role as a protein that exhibits cell cycle
regulation and inhibition of apoptosis (Knauer et al., 2007). It is expressed in the G2/M phase of cell cycle to support the rapidly dividing cell machinery (Kawata et al., 2011). Importantly, survivin is generally expressed in embryonic tissues; therefore, lack of survivin function results in disorganized and embryonal death (Borges et al., 2010; Upadhyay et al., 2011).

Recently, some investigators have found evidence of survivin expression in normal adult cells; therefore, it has been speculated that it may also have a role in normal cellular function (Yang et al., 2009b; Bayram et al., 2011).

The survivin gene in humans spans 14.7 kb located at the telomeric region of chromosome 17q25 (Ambrosini et al., 1998). Several single-nucleotide polymorphisms (SNPs) were identified within the promoter region of the survivin gene. A polymorphism at position -31 that involves the substitution of G for C (rs 9904341) has been the most documented in previous reports (Ma et al., 2011). This polymorphism is located at the cell cycle-dependent elements and cell cycle homology region repressor-binding motif of the promoter (Ma et al., 2011), and this mutation (G/C) seems to be correlated with increased expression of survivin at both transcription and translation levels (Lo and Farina, 2005; Ma et al., 2011). Also, many other survivin promoter polymorphisms, including -644T>C, -625G>C, and -241T>C, have been reported to be in linkage disequilibrium with -31G>C (Yang et al., 2009b).

Several case–control studies have examined the association between -31G/C polymorphism and cancer risk (Srivastava et al., 2012), including nasopharyngeal carcinoma (Yang et al., 2009a), esophageal cancer (Yang et al., 2009b), gastric cancer (Yang et al., 2009a; Borges et al., 2010), hepatocellular carcinoma (Bayram et al., 2011), pancreatic cancer (Theodoropoulos et al., 2010), and urothelial carcinoma (Wang et al., 2009). Immunohistochemical staining for survivin expression in tissue samples of thyroid carcinoma has shown the increased expression of survivin in thyroid carcinoma (Haghpahan et al., 2009). In a study on 110 patients with oral SCC, survivin expression was observed in 82.7% of patients, and all cases with metastatic carcinoma were positive for survivin expression. Reduced survivin expression was associated with long-term survival (Lo et al., 2003), indicating the relationship between survival and more aggressive tumor behavior and disease severity (Lo et al., 2003). According to the critical role of survivin in carcinogenesis with prognostic and its therapeutic implications (Dai et al., 2010), we evaluated the correlation of this polymorphism with pathological finding in tongue SCC in an Iranianian population.

Materials and Methods

Study population

Formalin-fixed, paraffin-embedded tissue sections were recruited from the archive of pathology department, Amir-Alam hospital, after being examined by an expert pathologist. Staging for tongue SCC was defined according to the American Joint Committee on Cancer (AJCC) and follows TNM staging. The case group consisted of patients with tongue SCC (n=91). The study was approved by the Ethics committee of Tehran University. Informed consents were obtained from all of the patients in the study.

DNA extraction and genotyping

DNA was extracted from paraffin-embedded tissue sections as described previously (Zahedi et al., 2012). The 151-bp DNA fragment containing the -31 polymorphic site amplified using pairs of primers as follows: 5’-AAAGGGCCGTTCCTCCCGACA-3’ and 5’-GAGATCGCGGTGTCCTTGAGAAA-3’.

The polymerase chain reaction (PCR) was performed in a total volume of 20 μL containing 2 μL × PCR buffer (Fermentas), 2.5 mM MgCl2, 0.2 mM dNTPs, 0.375 μM of each primer, 200 ng genomic DNA, and 1 U of Taq DNA polymerase (Fermentas).

The amplification conditions were as follows: denaturation at 95°C for 10 min; five cycles of 95°C for 45 s; and 72°C for 60 s for primer annealing, followed by 30 cycles of 94°C for 45 s, 62°C for 45 s, and 72°C for 45 s, with a final elongation at 72°C for 10 min. The PCR product size was 151 bp.

Eight microliters of PCR product was digested with 5 u MspI at 37°C overnight. Digested products yielding a 151-bp uncut fragment for the GG genotype, two fragments of 61 and 90 bp for the CC genotype, and three fragments of 151, 90, and 61 bp for the CG genotype were visualized on a 4% agarose gel stained with ethidium bromide.

Statistical analysis

Strength of association between different groups and alleles or genotypes of the survivin gene polymorphism was estimated using odds ratios (ORs) and 95% confidence intervals (CIs). Levels of significance were determined using contingency tables by either Chi-square or Fisher exact analysis. All analyses were carried out using STATA version 8.

Results

The mean age of patients was 55.7 ± 16.4 years, and women accounted for 49% and men 51% of the study population. Among our patients, 86% accounted for well-differentiated tumors. None of the patients presented with metastasis while nodal involvement was reported in 66% of patients. The clinical characteristics of patients are given in Table 1.

Survivin gene – 31 G/C polymorphism allele and genotype frequencies in patients with tongue SCC

The allele and genotype frequencies of the survivin gene -31G/C polymorphism were determined in patients with tongue SCC. When we compared the frequency of the survivin gene polymorphism in patients with stages III and IV to patients with stages I and II, we observed that the frequency of the GC or CC genotype was significantly higher in patients with stages III and IV [GC + CC vs. GG, p = 0.025, OR 2.76, 95% CI (1.03–7.4)] (Table 2). In addition, presence of allele C was significantly decreased in patients with T1 tumor size (23%) compared to patients with larger tumor size (48%) (p = 0.03, OR 0.6, 95% CI [0.2–2.03]) (data not shown).

Although there was an increase in the frequency of the GC or CC genotype in patients with lymph node involvement (55%) compared to patients without lymph node involvement (33%), it did not reach a significant level ([p = 0.05, OR 2.4, 95% CI (0.8–6.6)]) (data not shown).
There was no significant association between the survivin gene polymorphism and pathological grade in our population.

**Discussions**

Our results suggest that the survivin C–31G polymorphism was associated with stage of disease in our patients with tongue SCC. The increased expression of survivin in oral SCC and epithelial dysplasia has been reported, indicating its role in tumor aggressiveness and prognosis (Lin et al., 2005; Bang et al., 2008). In another study on laryngeal SCC, improvement was observed in patients treated with Silibinin, which decreased survivin expression (Bang et al., 2008).

In basal cell carcinoma of the larynx, survivin expression was related to recurrence and cases with poor prognosis requiring closer follow-up and more aggressive treatment (Marioni et al., 2006).

Functional studies have previously investigated the effect of the −31G/C polymorphism using a luciferase assay, indicating that the G allele decreased promoter activity compared with the C allele in Hela and CHO cells (Jang et al., 2008). Allele C was shown to be correlated with over-expression of survivin at both mRNA and protein levels and also with cell cycle-dependent transcription in various cancer cell lines (Gazouli et al., 2009). Our finding is in keeping with previous studies showing the C allele as a risk of developing various carcinomas. We have recently studied the association between this polymorphism and papillary thyroid carcinoma (PTC) and found that this polymorphism was a predisposing factor in PTC, and a more significant increase in the frequency of allele C was observed in patients with profound manifestations, including lymph node involvement, vascular involvement, and multifocality (Yazdani et al., 2012). Also, we observed strong association between this polymorphism and endometrial cancer (Zahedi et al., 2011). The association between the survivin gene polymorphism and pathological grading in our population, which might be due to the small number of patients in poorly differentiated and moderately differentiated groups. More studies on a larger number of samples and on other groups of patients with benign lesions of the oral cavity are required to further confirm the results we have observed in this study.

**Author Disclosure Statement**

No competing financial interests exist.

**References**


Address correspondence to:
Mahsa M. Amoli, M.D., Ph.D., EMRC
Endocrinology and Metabolism Research Center
Tehran University of Medical Sciences
Dr. Shariati Hospital
North Kargar Street
Tehran 14114
Iran
E-mail: amolimm@tums.ac.ir

Nasrin Yazdani, M.D.
Otorhinolaryngology Research Center
Amir Alam Hospital
Tehran University of Medical Sciences
North Saadi Avenue, P.O. Box 11457-65111
Tehran 14114
Iran
E-mail: n_yazdani@tums.ac.ir